Holen Sie sich die Stockscreener-App
8.50
7.91%
-0.73
Handel nachbörslich:
8.39
-0.11
-1.29%
Schlusskurs vom Vortag:
$9.23
Offen:
$9.2
24-Stunden-Volumen:
873.96K
Relative Volume:
2.08
Marktkapitalisierung:
$82.64M
Einnahmen:
$21.73M
Nettoeinkommen (Verlust:
$-91.17M
KGV:
-8.3333
EPS:
-1.02
Netto-Cashflow:
$-286.43M
1W Leistung:
+34.07%
1M Leistung:
+40.26%
6M Leistung:
-50.22%
1J Leistung:
-67.80%
1-Tages-Spanne:
$7.9401
$9.80
1-Wochen-Bereich:
$5.97
$9.80
52-Wochen-Spanne:
$5.80
$38.40
Bluebird Bio Inc Stock (BLUE) Company Profile
Firmenname
Bluebird Bio Inc
Sektor
Branche
Telefon
339-499-9300
Adresse
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Vergleichen Sie BLUE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
8.50 | 82.64M | 21.73M | -91.17M | -286.43M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-11-15 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-08-15 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-12-11 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2023-12-08 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-17 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-19 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-01 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-04-28 | Eingeleitet | JP Morgan | Overweight |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-08-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-08-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-04-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-07 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-11-08 | Bestätigt | Barclays | Equal Weight |
| 2021-11-08 | Bestätigt | Canaccord Genuity | Hold |
| 2021-11-08 | Herabstufung | Goldman | Neutral → Sell |
| 2021-11-08 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-11-08 | Bestätigt | Wedbush | Neutral |
| 2021-11-08 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-08-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-08-10 | Herabstufung | Goldman | Buy → Neutral |
| 2021-08-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-08-10 | Fortgesetzt | William Blair | Mkt Perform |
| 2021-08-09 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-01 | Herabstufung | Berenberg | Buy → Hold |
| 2021-03-10 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-02-17 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-02-16 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-02-16 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-12-09 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-05 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-11-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-11-05 | Herabstufung | Stifel | Buy → Hold |
| 2020-11-02 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2020-10-20 | Eingeleitet | Mizuho | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-27 | Hochstufung | Stifel | Hold → Buy |
| 2020-02-19 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-02-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-02-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-13 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-11-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-11-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-04 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Hold |
| 2019-08-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2019-06-18 | Hochstufung | Maxim Group | Hold → Buy |
Alle ansehen
Bluebird Bio Inc Aktie (BLUE) Neueste Nachrichten
bluebird bio (NASDAQ:BLUE) Coverage Initiated by Analysts at StockNews.com - MarketBeat
Gene Therapy For Rare Disease Market Overall Study Report - openPR
bluebird bio, Inc. (NASDAQ:BLUE) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Gene Therapy Market Huge Growth in Future Scope 2024-2031 | - openPR
Baird cuts bluebird bio price target on near-term dilution By Investing.com - Investing.com Canada
bluebird bio (NASDAQ:BLUE) Shares Up 15.3%Time to Buy? - MarketBeat
Baird cuts bluebird bio price target on near-term dilution - Investing.com
Cell and Gene Therapy Drug Delivery Devices Market to Witness - openPR
Bluebird Bio's SWOT analysis: gene therapy firm's stock faces cash crunch By Investing.com - Investing.com South Africa
Bluebird Bio's SWOT analysis: gene therapy firm's stock faces cash crunch - Investing.com
bluebird bio (NASDAQ:BLUE) Shares Down 13.4%Time to Sell? - MarketBeat
Bluebird Bio presents long-term data on LYFGENIA gene therapy for SCD - MSN
Bluebird bio CEO Andrew Obenshain sells $405 in stock By Investing.com - Investing.com South Africa
Cell and Gene Therapy Market is Dazzling Worldwide and Forecast - openPR
Bluebird bio CEO Andrew Obenshain sells $405 in stock - Investing.com India
Growing Demand and Trends of Advanced Cell Therapy - openPR
bluebird bio (NASDAQ:BLUE) Coverage Initiated at StockNews.com - MarketBeat
Bluebird bio Gets Nasdaq Noncompliance Notice - Marketscreener.com
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition - Business Wire
BLUEbluebird bio, Inc. Latest Stock News & Market Updates - StockTitan
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult H - Yahoo Finance
CMS enters agreement with Vertex, bluebird to improve access to gene therapies - Reuters
bluebird bio announces 1-for-20 reverse stock split; shares tumble - MSN
Bluebird Bio announces 1-for-20 reverse stock split - TipRanks
bluebird bio Announces 1-for-20 Reverse Stock Split - Business Wire
FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program - Benzinga
BLUE (bluebird bio) 3-Year FCF Growth Rate : 34.80% (As of Sep. 2024) - GuruFocus.com
Bluebird and Vertex's sickle cell gene therapies to kick off new Medicaid access model - Endpoints News
CMS rolls out new payment model for Vertex, bluebird gene therapies (NASDAQ:BLUE) - Seeking Alpha
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model - Business Wire
bluebird bio (NASDAQ:BLUE) Now Covered by StockNews.com - MarketBeat
Gene Therapy And Secondary Malignancies: Integration Site Analysis Can Only Be Part Of The Answer - News & Insights
FDA considers 'regulatory action' for bluebird's Skysona after blood cancer reports - FiercePharma
Bluebird’s Gene Therapy Skysona Under FDA Safety Probe for Hematologic Malignancies - BioSpace
Gene Therapy: Lyfgenia Voucher Denial Puts Sickle Cell Treatment At Risk, Bluebird Bio Says - News & Insights
FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy - Yahoo Finance
FDA investigating safety risks of bluebird's Skysona - MSN
FDA probes blood cancer risk from bluebird's gene therapy, weighs regulatory action - Reuters
FDA investigating safety risks of bluebird's Skysona (NASDAQ:BLUE) - Seeking Alpha
bluebird bio extends selloff as BofA and J.P. Morgan cut after Q3 results - MSN
bluebird bio, Inc. (NASDAQ:BLUE) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Adrenoleukodystrophy Treatment Market Global Share, Trends, - openPR
Bluebird Bio's SWOT analysis: gene therapy firm faces cash crunch amid launch - Investing.com
Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates - MSN
bluebird bio says seeking more cash to achieve cash flow break-even - MSN
Layoff Tracker: Adaptimmune Downsizes by 33% in Strategic Realignment - BioSpace
Adoptive Cell Therapy Market Industry Insights: Market Size, - openPR
StockNews.com Begins Coverage on bluebird bio (NASDAQ:BLUE) - MarketBeat
B of A Securities Downgrades bluebird bio (BLUE) - MSN
bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
bluebird bio downgraded by Bank of America, shares tumble - Proactive Investors Australia
Finanzdaten der Bluebird Bio Inc-Aktie (BLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bluebird Bio Inc-Aktie (BLUE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Colvin Richard A | Chief Medical Officer |
Dec 10 '24 |
Sale |
0.42 |
2,824 |
1,178 |
165,544 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):